These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25749049)

  • 1. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
    Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
    Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
    Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
    PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
    Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
    Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
    Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
    Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
    Cheah PL; Looi LM; Chan LL
    Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
    Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.
    Perlman EJ; Gadd S; Arold ST; Radhakrishnan A; Gerhard DS; Jennings L; Huff V; Guidry Auvil JM; Davidsen TM; Dome JS; Meerzaman D; Hsu CH; Nguyen C; Anderson J; Ma Y; Mungall AJ; Moore RA; Marra MA; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Gastier-Foster JM; Ross N; Smith MA
    Nat Commun; 2015 Dec; 6():10013. PubMed ID: 26635203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of CRABP-II expression by MycN in Wilms tumor.
    Gupta A; Kessler P; Rawwas J; Williams BR
    Exp Cell Res; 2008 Dec; 314(20):3663-8. PubMed ID: 18955045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
    Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
    Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.
    Natrajan R; Reis-Filho JS; Little SE; Messahel B; Brundler MA; Dome JS; Grundy PE; Vujanic GM; Pritchard-Jones K; Jones C
    Cancer Res; 2006 Dec; 66(23):11148-55. PubMed ID: 17145858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.
    Busch M; Schwindt H; Brandt A; Beier M; Görldt N; Romaniuk P; Toska E; Roberts S; Royer HD; Royer-Pokora B
    Hum Mol Genet; 2014 Aug; 23(15):3958-74. PubMed ID: 24619359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.
    Halliday BJ; Fukuzawa R; Markie DM; Grundy RG; Ludgate JL; Black MA; Skeen JE; Weeks RJ; Catchpoole DR; Roberts AGK; Reeve AE; Morison IM
    PLoS Genet; 2018 Jun; 14(6):e1007399. PubMed ID: 29912901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.
    Szemes M; Melegh Z; Bellamy J; Park JH; Chen B; Greenhough A; Catchpoole D; Malik K
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN and MAX alterations in Wilms tumor and identification of novel N-MYC interaction partners as biomarker candidates.
    Jiménez Martín O; Schlosser A; Furtwängler R; Wegert J; Gessler M
    Cancer Cell Int; 2021 Oct; 21(1):555. PubMed ID: 34689785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
    Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
    Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.
    Bardeesy N; Falkoff D; Petruzzi MJ; Nowak N; Zabel B; Adam M; Aguiar MC; Grundy P; Shows T; Pelletier J
    Nat Genet; 1994 May; 7(1):91-7. PubMed ID: 8075648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutional 560.49 kb chromosome 2p24.3 duplication including the MYCN gene identified by SNP chromosome microarray analysis in a child with multiple congenital anomalies and bilateral Wilms tumor.
    Micale MA; Embrey B; Macknis JK; Harper CE; Aughton DJ
    Eur J Med Genet; 2016 Dec; 59(12):618-623. PubMed ID: 27794475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
    Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
    Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.